Molecular Health to present at upcoming congresses

Newsroom

All news

Molecular Health to present at upcoming congresses

 

  • Molecular Health will attend several upcoming conferences in Europe and the US
  • Leading experts from the Company to present on AI in drug repurposing and evidence-driven decision support in research and clinical care

Heidelberg – September 19, 2019 – Molecular Health, a leading company in the field of data science for precision medicine and specializing in the development of products and services leveraging its proprietary biomedicine technology platform Dataome, is due to participate in several upcoming conferences between September and December, 2019. Company executives will give talks and participate in panel discussions on the use of artificial intelligence in the medical sector. The Company will present its product MH Predict, which assesses the likelihood of success of clinical trials. Moreover, it can be used for in silico-driven validation to identify drugs that can potentially be repurposed to treat other conditions. Further, Molecular Health will discuss its strategies for content curation in database generation and maintenance. Information on MH Guide, the company’s product to support physicians in selecting the optimal treatment for patients with cancer, will be available at several conferences. In addition, Dr. Friedrich von Bohlen, CEO of Molecular Health will participate in a panel discussion on the fusion of medicine and artificial intelligence at ‘Wissenswerte’ in Bremen. Please see below for details on the presentations as well as conferences where Molecular Health will host booths and will be available to discuss the range of applications of Dataome.

Drug Repurposing and Clinical Trial Success Prediction

Talk: ”Novel Approach to Drug Repurposing by Mining Safety Data and AI-based Simulation of Clinical Trials”

Clinical observations have historically been one of the most prominent sources for drug repurposing hypotheses. Molecular Health has taken the FDA’s vast set of clinical safety reports, cleaned and mapped them to their knowledge base of drugs, targets and pathways, and leveraged the analytics of their software application MH Effect to rapidly identify drug candidates.

In this talk, Prof. Armin Schneider, MD, PhD, SVP Scientific & Medical Affairs Molecular Health, will present Molecular Health’s proprietary approach to identify repurposing candidates, presenting examples of repurposing projects in tuberculosis and neonatal health.

Furthermore, he will showcase an in silico feasibility assessment by simulating clinical trial success using Molecular Health’s AI-driven software MH Predict, to support valuation and planning of the repurposed drug’s development program.

Monday, September 23, 2019, 10:30 – 11:00 am

8th Annual Drug Repositioning and Repurposing Conference | Washington, DC | September 23-24, 2019

            Venue:           The Westin Arlington Gateway, 801 North Glebe Road, Arlington, VA 22203, USA

            Speaker:        Prof. Armin Schneider, MD, PhD, SVP Scientific & Medical Affairs Molecular Health

            Program:      https://www.drugrepositioningconference.com/index/agenda

Talk: Predict R&D success. With AI

Around 85% of potential drugs entering Phase I clinical trials are destined to fail[1]. With MH Predict, Molecular Health has recently launched an AI tool that can predict the probability of success of clinical trials. In this talk, Prof. Armin Schneider will introduce Molecular Health’s proprietary prediction software and will discuss its application in a range of different scenarios. MH Predict can be used in the design of clinical trials to optimize key parameters as well as to predict trial success. In addition to analyzing a company’s own trials, the evaluation of clinical trials of competitors is another use case. Portfolio management and asset search and evaluation can also profit from Molecular Health’s software. Finally, MH Predict is able to perform in silico-driven hypothesis assessments, evaluate drug combinations in silico to improve treatment strategies, and identify candidates for drug repurposing.

[1]           Smietana, Katarzyna & Siatkowski, Marcin & Møller, Martin. (2016). Trends in clinical success rates. Nature Reviews Drug Discovery. 15. 10.1038/nrd.2016.85.

 

Thursday, September 26, 2019, 9:00 am

European Business Development Conference 2019 | Heidelberg, Germany | September 25-26, 2019

            Venue:           Deutsches Krebsforschungszentrum (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany

            Speaker:        Prof. Armin Schneider, MD, PhD, SVP Scientific & Medical Affairs Molecular Health

            Program:      https://www.biodeutschland.org/de/european-business-development-conference-2019.html

 

Wednesday, December 4, 2019, 3:30 pm

BioData World Congress 2019 | Basel, Switzerland | December 4-5, 2019

          The world’s leading congress for big data & AI in life science and healthcare

           Venue:           Basel Congress Center, Messeplatz 21, 4058 Basel, Switzerland

           Speaker:        Prof. Armin Schneider, MD, PhD, SVP Scientific & Medical Affairs Molecular Health

           Program:       https://www.terrapinn.com/conference/biodata/agenda.stm

           Booth:           Molecular Health is Silver Sponsor and exhibitor. Visit us at booth # 22

 

Digital Health and Database Content Development

Talk: “Digital Health – Wo Medizin und KI verschmelzen“
(”Digital Health – Where Medicine and AI Merge“)
During Germany’s most important conference for science journalism, Dr. Friedrich von Bohlen, CEO Molecular Health, will participate in a panel discussion on the role of artificial intelligence in today’s health landscape.

Tuesday, November 26, 2019, 10:45 am – 12:15 pm

Wissenswerte | Bremen, Germany | November 25-26, 2019

           Venue:           Congress Centrum Bremen, Borgward Saal, Theodor-Heuss-Allee 15, 28215 Bremen, Germany

           Panelist:        Dr. Friedrich von Bohlen, CEO Molecular Health

           Program:      https://wissenswerte-bremen.de/sessions/#rdv-calendar

 

Talk: “Evidence-driven decision support in research and clinical care –
Content development technology & strategy for ‘smart’ applications in regulated and exploratory medical environments”
Personalized genomic information and the large amount of research published in this field supports the entire value chain of medication: From pre-clinical research to clinical trials and eventually to treatment decisions made in the clinical practice. To support the seamless use of IT applications to deliver the right piece of information in response to a specific expert question, Molecular Health identified the need for – and set up –a canonical knowledge repository and reference system.

However, to be useful in an industrial setup, content engineering needs to balance manual data curation vs. automated content extraction, and data quality vs. data coverage. In the presentation, Molecular Health will therefore demonstrate the use of text-analytics AI and a collaborative data-curation platform in support of content production. Furthermore, commercial applications will be portrayed, ranging from a ‘medical device’ certified for evidence-based treatment decision support to an AI system to predict and analyze the likelihood of success of clinical trials.

Thursday, December 5, 2019, 12:00 – 12:20 pm

ConTech 2019 | London | December 5-6, 2019

           Venue:           Millenium Gloucester Hotel, 4-18 Harrington Gardens, South Kensington, London SW74LH, UK

           Speaker:        Dr. Mathias Goeschl, VP of Digital Content, Molecular Health
           https://contechlive.com/speakers/mathias-goeschl-molecular-health-gmbh/

           Program:      https://contechlive.com/event/contech-2019/

 

MH Guide

Molecular Health will host booths to present and discuss its genome-guided cancer treatment decision support software MH Guide at the industry exhibitions of the following conferences:

 

ESMO Congress 2019 | Barcelona, Spain | September 27 – October 01, 2019
             Translating science into better cancer patient care.

             Molecular Health is an exhibitor. Visit us at booth # 461, hall 3

 

AMP 2019 Annual Meeting & Expo | Baltimore, MD (USA) | November 7-9, 2019
             Premier gathering for molecular professionals.
             Molecular Health is exhibitor. Visit us at booth # 2323

 

 

About Molecular Health

Molecular Health is a data science-focused artificial intelligence computing company enabling and improving decision making in precision medicine for healthcare organizations. The company offerings are based on the capture, curation, integration, and analysis of large biomedical and drug data sets and combining them with novel artificial intelligence and machine learning (AI/ML) technologies. For more than a decade, the company has been developing Dataome, a unique high-quality curated, interoperable system that combines clinico-molecular and drug data with proprietary analytical processes. Dataome – stand alone or in combination with customer data – enables the unlocking of actionable intelligence at the molecular level to a) improve diagnosis and therapy decisions by physicians and patients; b) enrich and support better drug discovery, drug development, trial optimization, drug differentiation and positioning for pharma and healthcare organizations; and c) more accurately predict the likelihood of success and likelihood of approval of drug candidates in clinical development for better trial prioritization and resource and investment allocation.

For more information, visit www.molecularhealth.com.

 

Molecular Health GmbH

Thomas König

Head of Marketing & PR

thomas.koenig@molecularhealth.com

Media Relations

MC Services AG

Katja Arnold, Eva Bauer

molecularhealth@mc-services.eu

+49-89-210 228 0

https://www.molecularhealth.com

 

Radioimmunotherapy in Non-Hodgkin’s Lymphoma: Retrospective Adverse Event Profiling of Zevalin and Bexxar

Publications

Radioimmunotherapy in Non-Hodgkin’s Lymphoma: Retrospective Adverse Event Profiling of Zevalin and Bexxar

by Christos Sachpekidis, David B. Jackson and Theodoros G. Soldatos

 

The power of RWD integration at Molecular Health – insights into the utility and safety of Radioimmunotherapy in Non-Hodgkin’s Lymphoma patients.

The development of monoclonal antibodies has dramatically changed the outcome of patients with non-Hodgkin’s lymphoma (NHL), the most common hematological malignancy. However, despite the satisfying results of monoclonal antibody treatment, only few NHL patients are permanently cured with single-agent therapies. In this context, radioimmunotherapy, the administration of radionuclides conjugated to monoclonal antibodies, is aimed to augment the single-agent efficacy of immunotherapy in order to deliver targeted radiation to tumors, particularly CD20+ B-cell lymphomas. Based on evidence from several trials in NHL, the radiolabeled antibodies 90Y-ibritumomab tiuxetan (Zevalin, Spectrum Pharmaceuticals) and 131I-tositumomab (Bexxar, GlaxoSmithKline) received FDA approval in 2002 and 2003, respectively. However, none of the two radioimmunotherapeutic agents has been broadly applied in clinical practice. The main reason for the under-utilization of radioimmunotherapy includes economic and logistic considerations. However, concerns about potential side effects have also been raised. Driven by these developments, we performed retrospective analysis of adverse events reporting Zevalin or Bexxar, extracted from the FDA’s Adverse Event Reporting System (FAERS) and the World Health Organization’s VigiBase repository. Our results indicate that the two radioimmunotherapeutic agents have both related and distinct side effect profiles and confirm their known toxicological considerations. Our work also suggests that computational analysis of real-world post-marketing data can provide informative clinical insights. While more prospective studies are necessary to fully characterize the efficacy and safety of radioimmunotherapy, we expect that it has not yet reached its full therapeutic potential in modern hematological oncology.

 

Pharmaceuticals 201912(4), 141; https://doi.org/10.3390/ph12040141

Precision Oncology – The Quest for Evidence.

Publications

Precision Oncology – The Quest for Evidence.

The molecular characterization of patient tumors provides a rational and highly promising approach for guiding oncologists in treatment decision-making. Notwithstanding, genomic medicine still remains in its infancy, with innovators and early adopters continuing to carry a significant portion of the clinical and financial risk. Numerous innovative precision oncology trials have emerged globally to address the associated need for evidence of clinical utility. These studies seek to capitalize on the power of predictive biomarkers and/or treatment decision support analytics, to expeditiously and cost-effectively demonstrate the positive impact of these technologies on drug resistance/response, patient survival, and/or quality of life. Here, we discuss the molecular foundations of these approaches and highlight the diversity of innovative trial strategies that are capitalizing on this emergent knowledge. We conclude that, as increasing volumes of clinico-molecular outcomes data become available, in future, we will begin to transition away from expert systems for treatment decision support (TDS), towards the power of AI-assisted TDS-an evolution that may truly revolutionize the nature and success of cancer patient care.

Cancer Drug Resistance. (J Pers Med. 2019 Sep 5;9(3). Soldatos, Kaduthanam, Jackson. doi: 10.3390/jpm9030043.

Molecular Health signs up HudsonAlpha Institute for Biotechnology as new US customer for MH Guide

Newsroom

All news

Molecular Health signs up HudsonAlpha Institute for Biotechnology as new US customer for MH Guide

 

Molecular Health signs up HudsonAlpha Institute for Biotechnology as new US customer for MH Guide

 

  • Molecular Health Guide (MH Guide) gains ground in important U.S. market
  • MH Guide easily translates complex genetic data to support intelligent personalized medical decisions

Heidelberg, Germany – May 31, 2019 – Molecular Health (MH), a leading company in the field of data science for precision medicine, today announced that the Company has signed up the HudsonAlpha Institute for Biotechnology (HudsonAlpha) as a new client for MH Guide. HudsonAlpha is a nonprofit institute dedicated to developing and applying scientific advances to health, agriculture, learning, and commercialization.

 

MH Guide enables smarter patient care decisions based on deeper and broader biomedical information: Molecular pathologists and human geneticists can interpret genetic data derived from different technologies, such as next-generation sequencing, and create clinical reports that include drug information and variant classifications in minutes – easily, confidently, and accurately. HudsonAlpha plans to use MH Guide to elucidate detailed information on mutations found in patient tumor samples.

 

Dr. Friedrich von Bohlen, Co-founder and CEO of Molecular Health, said: ”Molecular Health is increasing its footprint in the U.S. as we sign on important new clients for our products. We are delighted to welcome HudsonAlpha as a customer and look forward to contributing through MH Guide to the important work they are doing to advance science and healthcare.”

 

About MH Guide
MH Guide, the gold standard in genomic data processing and analysis, is a rich bioinformatics platform, allowing medical professionals to analyze variants in the context of a patient’s cancer disease or predisposition to support identification of the potentially most effective treatments or disease predispositions. Molecular Health integrates private and publicly available databases, peer-reviewed scientific literature, and genome studies to extract salient information categorized by gene variant, disease, indication, cancer pharmacogenetics, and other relevant clinical classifiers. The stringent quality process Molecular Health follows to annotate and create its medical content is what sets MH Guide apart. Clients retain ownership of all data at all stages of the analysis, including the analysis results, which can be provided in a variety of digital formats, and have access to all source evidence for the annotations provided by the system. MH Guide is the first software product approved as an IVD medical device by the EU and is currently eligible for reimbursement in the EU.

Molecular Health holds industry symposium at DGP Annual Meeting in Frankfurt

Newsroom

All news

Molecular Health holds industry symposium at DGP Annual Meeting in Frankfurt

Molecular Health is sponsor and exhibitor at the 103rd Annual Meeting of the German Society of Pathology in Frankfurt.

It holds a lunch symposium on „Scaling the analysis and interpretation of NGS data with the medical device MH Guide in a clinical setting“ (Saturday, June 15, 12:15-1:45 pm). Prof. M. Kanai (Kyoto University Hospital) and Prof. M. Hummel (Charité Institute of Pathology) share their experiences with MH Guide in daily clinical routine.

http://www.professionalabstracts.com/pathologie2019/Iplanner/#/grid

Target-Adverse Event Profiles to Augment Pharmacovigilance: A Pilot Study With Six New Molecular Entities

Target‐Adverse Event Profiles to Augment Pharmacovigilance: A Pilot Study With Six New Molecular Entities

Newsroom

All news

Target‐Adverse Event Profiles to Augment Pharmacovigilance: A Pilot Study With Six New Molecular Entities

Abstract

Clinical trials can fail to detect rare adverse events (AEs). We assessed the ability of pharmacological target adverse‐event (TAE) profiles to predict AEs on US Food and Drug Administration (FDA) drug labels at least 4 years after approval. TAE profiles were generated by aggregating AEs from the FDA adverse event reporting system (FAERS) reports and the FDA drug labels for drugs that hit a common target. A genetic algorithm (GA) was used to choose the adverse event (AE) case count (N), disproportionality score in FAERS (proportional reporting ratio (PRR)), and percent of comparator drug labels with an AE to maximize F‐measure. With FAERS data alone, precision, recall, and specificity were 0.57, 0.78, and 0.61, respectively. After including FDA drug label data, precision, recall, and specificity improved to 0.67, 0.81, and 0.71, respectively. Eighteen of 23 (78%) post-market label changes were identified correctly. TAE analysis shows promise as a method to predict AEs at the time of drug approval.

Association Between Serotonin Syndrome and Second-Generation Antipsychotics via Pharmacological Target-Adverse Event Analysis

Association Between Serotonin Syndrome and Second-Generation Antipsychotics via Pharmacological Target-Adverse Event Analysis

Newsroom

All news

Association Between Serotonin Syndrome and Second-Generation Antipsychotics via Pharmacological Target-Adverse Event Analysis

Abstract

Case reports suggest an association between second-generation antipsychotics (SGAs) and serotonin syndrome (SS). The US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) was analyzed to generate hypotheses about how SGAs may interact with pharmacological targets associated with SS. FAERS was integrated with additional sources to link information about adverse events with drugs and targets. Using Proportional Reporting Ratios, we identified signals that were further investigated with the literature to evaluate mechanistic hypotheses formed from the integrated FAERS data. Analysis revealed common pharmacological targets perturbed in both SGA and SS cases, indicating that SGAs may induce SS. The literature also supported 5-HT2A antagonism and 5-HT1A agonism as common mechanisms that may explain the SGA-SS association. Additionally, integrated FAERS data mining and case studies suggest that interactions between SGAs and other serotonergic agents may increase the risk for SS. Computational analysis can provide additional insights into the mechanisms underlying the relationship between SGAs and SS.

Comprehensive Benchmarking of SNV Callers for Highly Admixed Tumors